Parkinson's Disease Research

Parkinson's disease (PD) is a degenerative disease of the central nervous system that often impairs motor skills, speech, and other functions. Symptoms of the disease include resting tremor, bradykinesia and rigidity. The primary symptoms are the result of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Symptoms of the disease appear once 50-80% of dopamine neurons have died. Parkinson's disease is both chronic and progressive.

Parkinson's Disease Research Products Targets

Products for Parkinson's Disease Research - Page 72

  1. Cat.No. Product Name Information/Activity
  2. BCC7985 LY 2389575 hydrochloride 885104-09-6 LY 2389575 hydrochloride chemical structure
  3. BCC7627 LY 487379 hydrochloride 353229-59-1 LY 487379 hydrochloride chemical structure
  4. BCC6343 ML 289 1382481-79-9 ML 289 chemical structure
  5. BCC6345 ML 337 1443118-44-2 ML 337 chemical structure
  6. BCC6156 MNI 137 946619-21-2 MNI 137 chemical structure
  7. BCC7866 Xanthurenic acid Xanthurenic acid is a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus. Xanthurenic acid chemical structure
  8. BCC1487 Clozapine N-oxide (CNO) Activator of muscarinic DREAADs,Clozapine N-oxide is a pharmacologically inert metabolite of Clozapine, which is a potent <b>5-HT1C</b> receptor antagonist. Clozapine N-oxide (CNO) chemical structure
  9. BCC5702 ACPT-I 194918-76-8 ACPT-I chemical structure
  10. BCC7344 AMN 082 dihydrochloride The first selective mGlu<sub>7</sub> agonist AMN 082 dihydrochloride chemical structure
  11. BCC6550 L-AP4 L-APB is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively. L-AP4 chemical structure

Items 711 to 720 of 752 total